Fig. 3.

Reported benefits of glucagon-like peptide 1 receptor (GLP-1R) agonism on cardiovascular disease. A summary of the reported benefits of glucagon-like peptide 1 (GLP-1)-based therapies on reducing cardiovascular disease burden in patients and in experimental settings, and the postulated mechanisms as to how this was achieved. This figure is adapted from Tate and colleagues 9,11. ANP, atrial natriuretic peptide; eNOS, endothelial nitric oxide synthase; hs-CRP, high-sensitivity C-reactive protein; NO, nitric oxide; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial growth factor.